Publicaciones en colaboración con investigadores/as de University of Alabama at Birmingham (22)

2023

  1. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5

    Obesity, Vol. 31, Núm. 3, pp. 703-715

2022

  1. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

    Nature Medicine, Vol. 28, Núm. 10, pp. 2083-2091

2021

  1. Heterozygous ANKRD17 loss-of-function variants cause a syndrome with intellectual disability, speech delay, and dysmorphism

    American Journal of Human Genetics, Vol. 108, Núm. 6, pp. 1138-1150

2020

  1. Epilepsy and Electroencephalographic Abnormalities in SATB2-Associated Syndrome

    Pediatric Neurology, Vol. 112, pp. 94-100

  2. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

    Journal of the National Cancer Institute, Vol. 112, Núm. 1, pp. 46-54

2019

  1. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 12, pp. 899-911

  2. Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies

    Calcified Tissue International, Vol. 104, Núm. 2, pp. 193-200

2018

  1. Immunocompromised patients with acute respiratory distress syndrome: Secondary analysis of the LUNG SAFE database

    Critical Care, Vol. 22, Núm. 1

  2. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies

    Bone, Vol. 116, pp. 58-66

2016

  1. Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: Results from the MAGGIC individual patient data meta-analysis

    QJM, Vol. 109, Núm. 6, pp. 377-382

2015

  1. Candida infective endocarditis: An observational cohort study with a focus on therapy

    Antimicrobial Agents and Chemotherapy, Vol. 59, Núm. 4, pp. 2365-2373

  2. Mucosal Immunity in the Human Female Reproductive Tract

    Mucosal Immunology: Fourth Edition (Elsevier Inc.), pp. 2097-2124

  3. Sub-centimeter HER2-Positive Breast Cancer: How Small Is Too Small to Treat?

    Seminars in Oncology, Vol. 42, Núm. 4, pp. e67-e79

2014

  1. Effect of evolocumab or ezetimibe added to moderate- Or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial

    JAMA, Vol. 311, Núm. 18, pp. 1870-1882

2013

  1. Estradiol Reduces Susceptibility of CD4+ T Cells and Macrophages to HIV-Infection

    PLoS ONE, Vol. 8, Núm. 4

  2. Treatment of idiopathic pulmonary fibrosis with Ambrisentan: A parallel, randomized trial

    Annals of Internal Medicine, Vol. 158, Núm. 9, pp. 641-649

2007

  1. Teriparatide or alendronate in glucocorticoid-induced osteoporosis

    New England Journal of Medicine, Vol. 357, Núm. 20, pp. 2028-2039

2002

  1. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv

    Gene Therapy, Vol. 9, Núm. 4, pp. 256-262

2001

  1. An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites

    Gynecologic Oncology, Vol. 82, Núm. 1, pp. 57-63

  2. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications

    Clinical Cancer Research, Vol. 7, Núm. 8, pp. 2496-2504